

Original article

Antibiotic resistance pattern of bacteria causing urinary tract infection in a private medical college hospital, Dhaka

Siddiqua M¹, Alam AN², Akter S³, Ferdousi RS⁴

Abstract:

Background and objective: Urinary tract infection (UTI) is one of the frequently seen infections both in the world and in our country as well. *Escherichia coli* (*E. coli*) are most frequently isolated in complicated or uncomplicated, nosocomial or community acquired urinary tract infections. To guide the empirical therapy, the resistance pattern of *E. coli* responsible was evaluated throughout the period in this study. **Material and Method:** Urine samples from outpatient / inpatient department of Ibn Sina Medical College Hospital between 1st January, 2015 and 31st December, 2015 were retrospectively analyzed. Presence of $\geq 10^5$ colony forming units/ml in urine culture was considered as significant for UTI. Isolated bacteria were identified by standard laboratory techniques and antibiotic susceptibility testing was performed by Kirby-Bauer disk diffusion method using Clinical Laboratory Standard Institute (CLSI) criteria. **Result:** A total of 271 (13.4%) uropathogens were isolated. Overall *E. coli* accounted for 180 (66.42%) of all isolates. Resistance rates of *E. coli* to antimicrobial agents was demonstrated to be as follows: cefuroxime 82%, nalidixic acid 74%, azithromycin 56%, cefotaxime 52%, ceftazidime 50%, cefixime 47%, cotrimoxazole 43%, ceftriaxone 41%, ciprofloxacin 38%, amoxicillin-clavulanic acid 31%, cefepime 30%, and low resistance which ranges from 9 to 1% included gentamycin 9%, meropenem 3%, imipenem 2%, nitrofurantoin 2% and amikacin 1%. **Conclusion:** As resistance rates show regional differences, it is necessary to regularly monitor regional resistance pattern to determine the appropriate empiric antibiotic treatment. The national antibiotic usage policies must be reorganized according to data obtained from these studies.

Keywords: Urinary tract infection (UTI); Antibiotic resistance pattern; *Escherichia coli* (*E. coli*)

Bangladesh Journal of Medical Science Vol. 16 No. 01 January'17. Page : 42-47

Introduction:

Urinary tract infections (UTIs) are a major cause of morbidity world wide and second most common infectious disease in community. Approximately 150 million cases are diagnosed each year¹. It is estimated that about 35 % of healthy women suffer from symptoms of urinary tract infection at some point in their life. The incidence of UTI is greater in women as compared to men, which may be either due to anatomical predisposition or other host factors².

Vaginal colonization with uropathogens precedes most UTIs and also sexual activity, pregnancy, obstruction are among the other factors contributing to increasing frequency of UTI in female³.

UTI is commonly caused by *Escherichia coli*, *Proteus*, *Klebsiella*, *Enterococcus*, and *Enterobacter* spp⁴. Most frequently *Escherichia coli* are isolated in complicated or uncomplicated, nosocomial or community acquired urinary tract infections^{5,6,7}. Antimicrobial resistance among

1. Dr. Mahmuda Siddiqua, Associate Professor, Department of Microbiology, Ibn Sina Medical College, Dhaka.
2. Dr. Ahmed Nawsher Alam, Principal Scientific Officer, Institute of Epidemiology Disease Control and Research, Dhaka.
3. Dr. Sonia Akter, Assistant Professor, Department of Microbiology, Ibn Sina Medical College, Dhaka.
4. Professor Reena Saad Ferdousi, Head, Department of Microbiology, Ibn Sina Medical College, Dhaka.

Correspondence to: Dr. Mahmuda Siddiqua, Associate Professor, Department of Microbiology, Ibn Sina Medical College, Dhaka. **E-mail:** mahmuda99@yahoo.com

uropathogenic *E. coli* may be increased with temporal and geographic fluctuations which may introduce multidrug resistant *E. coli* into the community⁸. It has been recommended that guiding data adjusted to epidemiological data should be used in the selection of routine treatment^{5,9}. Therefore region-specific microorganisms and their antimicrobial susceptibilities should be determined.

Indiscriminate use of antimicrobial agents is a common practice in underdeveloped and many developing countries that often leads to emergence of resistant microorganisms. So, the scope for effective antibiotic to combat bacterial infections including UTI sgradually decreased¹⁰. As a common practice, empirical antimicrobial treatment is initiated before the laboratory results of urine culture are available which may lead to emergence and spread of antimicrobial resistant strains. Factually, antimicrobial resistance is one of the principal causes of treatment failure in infectious diseases and a great concern for UTIs¹¹. The prevalence and pattern of antimicrobial resistance of uropathogens are dependent on many factors. Continuous monitoring of resistance pattern is of paramount importance for not only selecting appropriate drugs but also for rational choice of empirical therapy¹².

The present investigation was carried out to determine the recent status of prevalence of bacterial pathogens and their antimicrobial resistance in UTI patients. The aim of this study is to guide physicians to provide information about choice of proper antibiotic for empirical treatment.

Material and methods:

A study was carried out in the Microbiology department of Ibn Sina Medical College Hospital from January 2015 to December 2015. Urine samples were collected from outpatient and inpatient department for routine microscopic examination and culture sensitivity. Culture plates were incubated at a mean ambient temperature of 35±2°C for 18–48 hours; bacterial growths of ≥10⁵ CFU/ml of a single species were examined. The isolates obtained were identified using conventional methods. Antimicrobial susceptibilities of isolated organisms were determined using Kirby-Bauer disc diffusion system, with the recommendations of Clinical and Laboratory Standards Institute (CLSI)¹³.

Identification of the uropathogens: Uropathogens were isolated on Blood agar and MacConkey agar media. All the plates were incubated aerobically at

35±2°C for 18–48 hours and the colonies were studied. For confirmation of specific bacterial spp., standard biochemical tests (MIU, KIA, Citrate, Catalase, Coagulase, bile aesculin test) were performed.

Antimicrobial susceptibility testing: Antimicrobial susceptibility testing of the isolated bacterial spp. was performed by disc diffusion method following the CLSI guidelines¹³. Antibiotic discs used as follows: amikacin (30µg), amoxyclave (30µg), azithromycin (15µg), cefepime (30µg), cefixime (05µg), cefotaxime(30µg), ceftazidime (30µg), cefuroxime (30µg), ceftriaxone (30µg), cotrimoxazole (25µg), cloxacillin (10µg), cephradine (30µg), nalidixicacid (30µg), ciprofloxacin (5µg), imipenem (10µg), meropenem (10µg), nitrofurantoin (300µg) and gentamicin (10µg). This study was approved by local ethics committee.

Results:

A total of 2021 urine samples from patients of different age and sex of suspected UTI were included in this study. Of 2021 cases, 600 (29.68 %) were male and 1421(70.32 %) were female. A total of 271(13.41 %) bacterial growths were isolated from 2021 urine samples. Rate of prevalence of uropathogens in male and female was 8.3% and 15.6 % respectively, with a male to female ratio of 1:4.4 (Table 1).

Table 1: Gender distribution and growth of uropathogens

Sex	No of Sample	Growth	No growth
Male	600 (29.68%)	50 (8.3%)	550 (91.7%)
Female	1421 (70.32%)	221(15.6%)	1200 (84.4%)
Total	2021 (100%)	271 (13.4%)	1750

E. coli was the predominant isolates 180 (66.42 %), followed by *Proteus* spp. 31 (11.44 %), *Klebsiella* spp. 22 (8.12 %), *Staphylococcus saprophyticus* 13 (4.80%), *Pseudomonas* spp. 11 (4.06 %), *Enterococcus* spp. 10 (3.69%) and *Staphylococcus aureus* 04 (1.48%), as shown in Table-2.

Table 2: Pattern of Bacterial Isolate from Urine Cultures

ORGANISM	Frequency	Percent
<i>E. coli</i>	180	66.42%
<i>Proteus</i>	31	11.44%
<i>Klebsiella</i>	22	8.12%
<i>Staph.saprophyticus</i>	13	4.80%
<i>Pseudomonas</i>	11	4.06%
<i>Enterococci</i>	10	3.69%
<i>Staph. Aureus</i>	4	1.48%
Total	271	100.00%

The antimicrobial resistance patterns of isolates are shown in Table 3. High frequency of resistance ranging from 30 to 82% to most of the drugs which included cefepime, amoxycylav, ciprofloxacin, ceftriaxone, cotrimoxazole, cefixime, ceftazidime, cefotaxime, azithromycin, nalidexic acid, and cefuroxime and low resistance which ranges from 9 to 1% included gentamycin (9%), meropenem (3%), imipenem (2%), nitrofurantoin (2%) and amikacin (1%) were shown by *E. coli*.

Proteus showed high frequency of resistance to most of the drugs like cefixime, azithromycin, ceftazidime, cefuroxime, nalidexic acid ranges from 30% to 73%, moderate resistance 16 to 29% to ciprofloxacin, cefepime, cefotaxime, ceftriaxone, amoxycylav, cotrimoxazole and low resistance to gentamycin (3%) and amikacin (3%). Meropenem and imipenem were found 100% sensitive.

Klebsiella showed high frequency of resistance to cefuroxime, ceftazidime, amoxycylav, cotrimoxazole, azithromycin, cefixime, cefotaxime, nalidexic acid, ceftriaxone, cefepime, ciporofloxacin ranges from

36 to 82%. Nitrofurantoin, gentamycin, meropenem and amikacin showed low resistance from 9 to 24%. Only imipenem was found 100% sensitive for this organism.

Staphylococcus saprophyticus was found resistant to few drugs, highest being to ceftazidime 85%, cefepime (58%), cefixime (54%), nalidexic acid (50%) and azithromycin (40%). Cephadrine, amikacin and imipenem were found 100% sensitive and rest of the drugs showed low resistance started from 8 to 25%.

No drug for *Pseudomonas* found to be 100% effective. All the used drugs showed resistance started from 9% (Imipenem) to 87% (Nitrofurantoin). Nalidexic acid, azithromycin, cotrimoxazole and cefotaxime were found 100% resistant to *Enterococci* and 83-80% for ciprofloxacin and cefepime. All other drugs were found resistant from 67 to 17%. Some drugs are seen to be 100% sensitive to *Staphylococcus aureus* like nitrofurantoin, gentamycin, amikacin and imipenem. Again 100% resistance was found for nalidexic acid.

Table 3: Antibiotic resistance pattern of uropathogens

Antimicrobial agents	<i>E.coli</i> N=180	<i>Proteus</i> N=31	<i>Klebsiella</i> N=22	<i>S.Saprophyticus</i> N=13	<i>Pseudomonas</i> N=11	<i>Enterococci</i> N=10	<i>S. aureus</i> N=4
	R* (%)	R (%)	R (%)	R (%)	R (%)	R (%)	R (%)
Amikacin	01	03	09	00	10	17	00
Amoxycylav	31	29	55	08	73	17	13
Cefepime	30	17	36	58	55	80	50
Cefixime	47	30	45	54	73	67	88
Cefotaxime	52	23	44	12	45	100	20
Ceftazidime	50	45	55	85	64	67	88
Cefuroxime	82	62	82	25	82	50	75
Ceftriaxone	41	26	41	08	36	50	25
Cephadrine	-	-	-	00	-	50	25
Ciporofloxacin	38	16	36	08	18	83	25
Cloxacillin	-	-	-	08	-	25	50
Cotrimoxazole	43	29	48	31	50	100	25
Gentamicin	09	03	18	08	27	17	00
Imipenem	02	00	00	00	09	33	00
Meropenem	03	00	16	18	27	50	12
Nalidexic acid	74	73	43	50	82	100	100
Nitrofurantoin	02	-	24	20	87	25	00
Azthromycin	56	41	46	40	64	100	57

*R=Resistance

Discussion:

Urinary tract infection is emerging as an important community acquired and nosocomial bacterial infection. Moreover, antimicrobial resistance to various classes of antimicrobials to uropathogens continues to be a major health problem in different parts of the world.^{14, 15}

Urinary tract infections (UTIs) are common in women, often associated with significant morbidity and mortality¹⁶ and may affect women of all age groups especially sexually active ones¹⁷. Our findings are also in agreement with this generalization and rightly coincided with a study done by Deshpande et al.¹⁸.

We studied 2021 urine samples and found significant growth in about 13.41% cases. The frequency is close to the incidence reported by Ahmed and Avasarala (2008), and Begum et al. (2006) 12.7% and 16.4% respectively^{19, 20}. The findings of this study is higher than the study of Singh MM et al. (2001)²¹ who reported 4.2% UTI in a community based study but lower than the study of Bashar et al. (2009), and Ahmed et al. (2016) who reported frequency of UTI is 27% and 24.85% respectively in hospital or clinic based study^{22, 23}.

E. coli is the most common uropathogen (66.42%) isolated from the cultured urine samples of this study population. This is similar to findings from studies done in other developing countries such as India (68%)²⁴ and Madagascar (67%)²⁵. Lower incidences from other studies observed like in India 59%²⁶ and 52.65%²⁷. Higher incidence found by Saber et al. 77.8%²⁸ and by Bosch et al. 75% in South Africa.²⁹

According to a guideline published by Infectious Diseases Society of America (IDSA) in the year 2011, treatment of acute uncomplicated cystitis in women with nitrofurantoin, fosfomycin, trimethoprim-sulfamethoxazole, and pivmecillinam can be initiated, if regional resistance rates against aforesaid antibiotics does not exceed 20% and in cases of suspect acute pyelonephritis fluoroquinolones or beta-lactame antibiotics.⁹

In Bangladesh the antibiotic resistance uropathogens has now become a public health concern.³⁰ If the patient doesn't maintain antibiotic dose regimen

properly, the organism may emerge as drug resistant variant and eventually result in both nosocomial and community acquired UTIs.^{31, 32} Increasing drug resistance is a great concern to common bacterial infections including UTI. For empirical use of antibiotic to treat uncomplicated UTI, many underdeveloped countries and developing countries like Bangladesh use antimicrobial agents like amoxicillin, cotrimoxazole, cephadrine, nalidixic acid, ciprofloxacin, azithromycin.³³ Unfortunately, it was found that all those agents had no acceptable range of sensitivity against *E. coli*. This finding is alarming for an effective agent to find out for treatment against UTI and very difficult situation for physicians as well. Only gentamycin, meropenem, imipenem, nitrofurantoin and amikacin were found to have good sensitivity. But in uncomplicated UTI injectable drug are not acceptable because of compliance, so gentamycin is not a drug of choice. Meropenem, imipenem and amikacin are not use routinely and are kept as reserve for critical situation. So, nitrofurantoin was found to be reasonably effective agent among all antimicrobials against *E. coli* in the current setting and similar findings were seen in other studies.^{34, 35, 36} Nitrofurantoin has some advantages too; it is cheap, can be taken orally. This study result clearly indicated that common drugs used against uncomplicated UTI are not effective for empirical treatment.

It needs to be considered whether the antimicrobial susceptibility profile of uropathogens identified in this study can be used as representative of the general situation in Bangladesh; if not, then more study to be done and real scenarios to be found out.

Conclusion:

Globally, the increasing rate of antibacterial resistance including our country is thought to be related to erroneous strategies of antibio-therapy. So it should be closely monitored both at the regional and national levels. As antibiotic resistance increasing, compared with previous years, there should be continued monitoring of this data to evaluate trend of resistance of antimicrobials for sustained optimization of empirical therapy.

Conflict of interest: None declared.

References:

1. Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India. *Ann Clin Microbiol Antimicrob.* 2007; **6**:4. <https://doi.org/10.1186/1476-0711-6-4>
2. Schaeffer AJ, Rajan N, Cao Q, Anderson BE, et al. Host pathogenesis in urinary tract infection. *Int J Antimicrob Agents.* 2001; **7**:245–51. [https://doi.org/10.1016/S0924-8579\(01\)00302-8](https://doi.org/10.1016/S0924-8579(01)00302-8)
3. Stamm WE. Urinary tract infections and pyelonephritis. In: Kasper DL, Braunwald E, Fauci AS, et al., editors. *Harrison's principles of internal medicine.* 16th ed. USA: McGraw-Hill companies Inc; 2005. p. 1715–21.
4. Guentzel MN. *Escherichia, Klebsiella, Enterobacter, Serratia, Citrobacter, and Proteus.* Barron's Medical Microbiology. 4th ed. Univ of Texas Medical Branch; 1996.
5. Arslan H. Komplikeolmayan, üriner sistem infeksiyonları: Rehberlyolgösterebiliyor mu? *ANKEM Derg.* 2012; **26**:158–62.
6. Gupta S, Kapur S, Padmavathi DV. Comparative prevalence of antimicrobial resistance in community-acquired urinary tract infection cases from representative States of Northern and Southern India. *J Clin Diagn Res.* 2014; **8**:9–12.
7. Kashaf N, EsmaeeliDjavid G, Shahbazi S. Antimicrobial susceptibility patterns of community-acquired uropathogens in Tehran, Iran. *J Infect Dev Ctries.* 2010; **4**:202–6. <https://doi.org/10.3855/jidc.540>
8. Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. *Clin Infect Dis.* 2001; **33**(1):89–94. <https://doi.org/10.1086/320880>
9. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis.* 2011; **52**:e103-20. <https://doi.org/10.1093/cid/ciq257>
10. Gold HS, Moellering RC. Antimicrobial drug resistance. *N Eng J Med.* 1996; **335**:1445–53. <https://doi.org/10.1056/NEJM199611073351907>
11. Gupta K. Addressing antibiotic resistance. *Am J Med.* 2002; **113**:295–345. [https://doi.org/10.1016/S0002-9343\(02\)01057-4](https://doi.org/10.1016/S0002-9343(02)01057-4)
12. Bauza E, Cercenado E. Klebsiella and Enterobacter antibiotic resistance and treatment implications. *Semin Respir Infect.* 2002; **17**:215–30. <https://doi.org/10.1053/srin.2002.34693>
13. Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing: sixteenth informational supplement 2006. CLSI document M100-S16 CLSI, Wayne, PA.
14. Oliveira FA, Paludo KS, Arend LNVS, Farah SMSS, Pedrosa FO, Souza EM, Surek M, Picheth G, Fadel-Picheth CMT. Virulence characteristics and antimicrobial susceptibility of uropathogenic *Escherichia coli* strains. *GenetMol Res.* 2011; **10**:4114–25. <https://doi.org/10.4238/2011.October.31.5>
15. Farshad S, Ranjbar R, Japoni A, Hosseini M, Anvarinejad M, Mohammadzadegan, R. Microbial susceptibility, virulence factors and plasmid profiles of uropathogenic *Escherichia coli* strains isolated from children in Jahron. Iran. *Arch Iran Med.* 2012; **15**:312–6.
16. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. *Am J Infect Control.* 1988; **16**(3):128-140. [https://doi.org/10.1016/0196-6553\(88\)90053-3](https://doi.org/10.1016/0196-6553(88)90053-3)
17. Foxman B, Zhang L, Tallman P et al. Transmission of uropathogens between sex partners. *J Infect Dis.* 1997; **175**(4): 989-992. <https://doi.org/10.1086/514007>
18. Deshpande KD, Pichare AP, Suryawanshi NM, Davane MS. Antibigram of gram negative uropathogens in hospitalized patients. *Int J Recent Trends Sci Technol.* 2011; **1**(2):56–60.
19. Ahmed SM, Avasarala AK. 2008. Urinary tract infections (UTI) among adolescent girls in rural Karimnagar district, AP – K.A.P. STUDY. *Indian J Prev Soc Med.* 39, 1-2: 67-70.
20. Begum N, Mamoon ABA, Hossain M, Begum N, Chowdhury SA, Rahman MF. UTI among female workers in a selected garment industry of Dhaka city: A cross sectional study. *The ORION Medical Journal.* 2006; **23**: 325-327.
21. Singh MM, Devi R, Garg S, Mehra M. Effectiveness of syndromic approach in management of reproductive tract infections in women. *Indian J Med Sci.* 2001; **55**(4): 209-214.
22. Bashar MA, Ahmed MF, Rahman SR, Gomes DJ. Distribution and Resistance Trends of *Escherichia coli* from Urinary Tract Infections Isolated in Dhaka City. *Ban J Med Sci.* 2009; **15**(2): 93-98.
23. Ahmed A A, Alam A N, Fatmi R, Rahman MM, Munia MS, Juyee N A. 2016. Antibiotic Sensitivity pattern of uropathogens at Khwaja Yunus Ali Medical College Hospital. *Journal of Khwaja Yunus Ali Medical College.* 2016; **6**(2):610-13.
24. Kothari A, Sagar V. Antibiotic resistance in pathogens causing community acquired urinary tract infections in India: A multicenter study. *J Infect Dev Ctries.* 2008; **2**(5):354–358. <https://doi.org/10.3855/jidc.196>
25. Randrianirina F, Soares JL, Carod JF, et al. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Antananarivo, Madagascar. *J Antimicrob Chemother.* 2007; **59**(2):309–312. <https://doi.org/10.1093/jac/dkl466>
26. DH, Dhanorkar DV, Gulhane SR, et al. Antibacterial susceptibility of some urinary tract pathogens to commonly used antibiotics. *Afr J Biotechnol.* 2006; **5**(17):1562–1565.
27. Jan N, Meshram SU & Kulkarni A. Plasmid profile

- analysis of multidrug resistant *E. coli* isolated from UTI patients of Nagpur City, India. *Romanian Biotechnological Letters*. 2009; **14**(5): 4635-4640.
28. Saber MH, Barai L, J Haq A, Jilani MSA & Begum MJ. The Pattern of Organism Causing Urinary Tract Infection in Diabetic and Non Diabetic Patients in Bangladesh. *Bangladesh J Med Microbiol*. 2010; **04**(01): 6-8.
 29. Bosch FJ, van Vuuren C, Joubert G. Antimicrobial resistance patterns in outpatient urinary tract infections – the constant need to revise prescribing habits. *S Afr Med J*. 2011; **101**(5):328–331. PMID:21837876 <https://doi.org/10.7196/SAMJ.4346>
 30. Rahman MM, Haq JA, Hossain MA, Sultana R, Islam F, Islam AH. Prevalence of extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in an urban hospital in Dhaka, Bangladesh. *Int J Antimicrob Agents*. 2004; **24**(5):508-510. <https://doi.org/10.1016/j.ijantimicag.2004.05.007>
 31. Gales AC, Gordon KA, Wilke WW, Pfaller MA, Jones RN. Occurrence of single-point *gyrA* mutations among ciprofloxacin susceptible *Escherichia coli* isolates causing urinary tract infections in Latin America. *Diagn Microbiol Infect Dis*. 2000; **36**(1): 61-64. [https://doi.org/10.1016/S0732-8893\(99\)00121-2](https://doi.org/10.1016/S0732-8893(99)00121-2)
 32. Gupta K, Stamm WE. Pathogenesis and management of recurrent urinary tract infections in women. *World J Urol*. 1999; **17**(6): 415-420. <https://doi.org/10.1007/s003450050168>
 33. Rezwana Haque, Most. Laila Akter and Md. Abdus Salam. Prevalence and susceptibility of uropathogens: a recent report from a teaching hospital in Bangladesh. *BMC Res Notes* (2015); **8**:416(1-5)
 34. Sharifian M, Karimi A, Rafiee-Tabatabaei S, et al. Microbial sensitivity pattern in urinary tract infections in children: a single center experience of 1177 urine cultures. *Jpn J Infect Dis*. 2006; **59**:380–2.
 35. Kothari A, Sagar V. Antibiotic resistance in pathogens causing community-acquired urinary tract infections in India: a multicenter study. *J Infect Dev Ctries*. 2008; **2**:354–8. <https://doi.org/10.3855/jidc.196>
 36. Sohely S, Farhana AF, Fahmida, Saleh AA. Sensitivity pattern of uropathogens in children. *Bangladesh J Med Microbiol*. 2009; **3**(1):18–22.
-